|
March 2009
GB Information publishes China Biotech 2009
GBI released China Biotech 2009, the insiders guide to China biotech, in March. Updated and expanded from the 2008 edition, this report provides an in-depth look at biotechnology R&D in China, industry statistics and indicators, and an authoritative database of China's biotechnology companies. China Biotech 2009 is essential for understanding China's emerging innovators, identifying potential clients and partners, and staying abreast of developments in this dynamic industry. More information can be obtained at www.gbipharma.com.
March 2009
GB presents at BioMedical Asia 2009
During BioMedical Asia 2009 held in Singapore, GB CEO Matthew Chervenak served as moderator for the panel discussion 'Perspective on the biotech/healthcare powerhouses of Asia-Part: China'. The discussion focused on identifying investment opportunities and trends in China's healthcare venture capital and private equity industry. Panelists included Liu Yuwen from Suzhou's BioBay, Carl Firth from Merrill Lynch, Victor Shi fromQiagen, and Nisa Lin of Qiming Ventures.
February 2009
GB Information releases SOURCE
This month, GBI officially released SOURCE, the ultimate information resource for professionals focused on China's pharmaceutical industry. SOURCE, intended to be the "Bloomberg Terminal of China pharmaceuticals", integrates current and historical data from a wide range of sources. Pharmaceutical producers, products, prices, tenders, reimbursement, policies, news, hospitals, and various tools and analytics are imbedded in an easy to use, single point access. SOURCE is designed to save pharmaceutical companies, investors, and analysts time and money while breading the knowledge base and boosting productivity. More information can be obtained at www.gbipharma.com.
December 2008
GB Information releases China Retail Pharmacies
GBI released China Retail Pharmacies report, an examination of China's independent retail pharmacy sector, in December. The report covers past and current trends in the market, policies, business practices, investments, case studies, and leading companies in the field. China Retail Pharmacies is necessary for pharmaceutical companies, analysts, investors, and other industry players looking for a wide and deep understanding of China's independent retail pharmacy sector. More information can be obtained at www.gbipharma.com.
July 2008
GB presents at Biosimilars Conference in Philadelphia
IBC held it’s 4th Biosimilars Conference in Philadelphia, Pennsylvania. GB CEO Matthew Chervenak gave a riveting presentation the opportunities and challenges for biologics in China, including discussion on the impact of the price in China, case studies, an outline of working businesses and sales models, and the road to FDA compliance and non-regulated markets.
May 2008
GB presents at Impact IV China Conference in Beijing
GB CEO Matthew Chervenak presented at Impact China: Pharmaceutical R&D Global Summit, discussing key opportunities in outsourcing and innovation in China's rapidly evolving biotechnology industry. A variety of companies attended the Beijing conference, notable for its comprehensive coverage of vital issues in China's R&D sector.
May 2008
Jonathan Zifferblatt joins the GB team!
General Biologic is pleased to welcome Dr. Jon Zifferblatt, MD/MPH as managing director. Jon brings a unique combination of business, healthcare, and biopharmaceutical experience to GB's multi-dimensional team. Jon has worked in management capacities in the pharmaceutical and investment banking sectors in both the US and China. Prior to joining GB, he was a vice president at ChinaVest, a merchant bank headquartered in Shanghai. Jon holds an MPH and an MBA from the University of California, Berkeley, as well as an MD from the University of California, San Diego School of Medicine.
April 2008
GB presents at Pharma Delegates in Tokyo
GB CEO Matthew Chervenak presented to a Pharma Delegates audience of Japanese pharmaceutical executives at the American Club in Tokyo, Japan. Matt covered China's rapidly expanding pharmaceutical market and industry, investment opportunities, and recent transactions in the country and presented options for Japan's pharmaceutical companies in terms of market, sourcing, and R&D.
February 2008
GB presents at IBC Antibody Engineering Conference
GB CEO Matthew Chervenak gave a talk at IBC's Antibody Engineering Conference, held this month in Singapore. Matt gave an overview of the tremendous strides that have been made in China's antibody industry over the past few years and spoke about the market and R&D opportunities for Chinese and multinational companies.
February 2008
GB Moves to New Office
GB moved to a new, expanded office located near Shanghai's XinTianDi. Gong strike to announce all visitors. Suite 301, Building 2, 169 Mengzi Road, Shanghai 200023, P.R. China. Phone +86 21 5302-2951, Fax +86 21 5302-2950.
January 2008
GB presents at Business Alliance FastTrack Forum
Business Alliance's FastTrack Forum was held in Tysons Corner, Virginia in January. The Forum included discussion of market and service opportunities in China. GB CEO Matthew Chervenak presented on opportunities for the pharmaceutical and biotechnology industry.
January 2008
GB Information publishes China Biotech 2008
GBI released China Biotech 2008 in January. Updated and expanded from the 2006 edition, this report provides an in-depth look at biotechnology R&D in China, industry statistics and indicators, and an authoritative directory of biotechnology companies. China Biotech 2008 is essential for understanding China's emerging innovators, identifying potential clients and partners, and staying abreast of developments in this dynamic industry. More information can be obtained at www.gbipharma.com.
January 2008
GB Information publishes China Molecular Diagnostics report
GBI released its Molecular Diagnostics report and database in January. The report covers market assessments, technology focus areas, industry trends, and policy updates and will benefit investors, buyers, vendors, and other molecular diagnostics players. The database includes more than 100 companies providing molecular diagnostic products and services in China and more than 50 Chinese domestic and multinational kit & instrument manufacturers. The database also includes contacts at key distributors and service providers. More information can be obtained at www.gbipharma.com.
December 2007
GB Information releases China Vaccine report
GBI published China Vaccine 2008, providing an in depth analysis of the human use vaccine industry and market in China. The market analysis covers the private payer sector and provides an in depth look at the National Immunization Program and the impact of the 10-fold increase in budget announced in 2007. Industry coverage includes profiles and analysis of the major domestic companies and research institutes. R&D and major technology initiatives are also addressed in the report. More information can be obtained at www.gbipharma.com.
August 2007
GB presents at AmCham's Healthcare and Science & Technology Committee
The Healthcare and Science & Technology Committees of the American Chamber of Commerce in Shanghai held Moving from "Made in China" to "Made by China": The Challenges & Opportunities of China's Focus on Innovation. GB CEO Matthew Chervenak presented on the topic of innovation in China from the perspective of multinational companies focused on the healthcare industry and also addressed biotechnology companies, research at China's institutes and universities, and licensing transactions.
April 2007
GB Information releases new edition of China Antibodies report
GBI released its updated and expanded China Antibody report, an essential resource for companies, investors, and entrepreneurs interested in accessing China's antibody industry. The report offers a comprehensive industry overview and market analysis, a directory of China's antibody-related enterprises, detailed case studies of industry leaders, and company profiles. The report also addresses cost data and large-scale manufacturing. More information can be obtained at www.gbipharma.com.
March 1, 2005
GB publishes its report on Bio-Distributors in China
GB analysts release "Bio-Distributors China 2005", a fundamental resource
for life science suppliers seeking to reach customers in China. The
report offers an overview of the industry environment for China's more
than 180 distributors. "This report provides the foundation from which
companies may craft an informed distribution strategy that maximizes
potential in this rapidly changing market." says GB President, Matthew
Chervenak.
February 1, 2005
GB releases its report on the antibody industry in China
"Antibodies in China" is an essential resource for companies, investors,
and entrepreneurs interested in accessing China's antibody industry.
This report offers a comprehensive overview and market analysis, together
with a directory of over 30 antibody-related enterprises. GB analysts
deliver detailed case studies of industry leaders, along with company
profiles. Cost data is included and large-scale manufacturing is also
addressed.
December 15, 2004
GB's China Pipeline featured in Nature Magazine article
In December's issue of Nature Magazine, Sabine Lou?t uses GB's unique
China Pipeline Report as a jumping off point in a close look at China's
burgeoning biotech industry. The article, "Can China bring its own pipeline
to the market?", focuses on the opportunities and dangers available
to industry players and investors, in a time of rapid innovation and
strengthening government regulation.
December 13, 2004
GB publishes Bio-Services in China
GB published Bio-Services in China today, the essential starting point
for any research enterprise, investor, or entrepreneur looking to increase
R&D productivity and reduce costs through outsourcing. The report
includes an overview of the industry, cost comparisons, 8 services categories
with company listings and critical equipment employed, 3 case studies,
15 profiles, and a directory of 53 Chinese biotech service companies.
As evidenced by Invitrogen's acquisition of Bioasia, there has never
been a better time to contemplate the advantages China can bring to
your organization.
November 10, 2004
GB publishes Emerging Bio-equipment Manufacturers in China
2004
GB published Emerging Bio-Equipment Manufacturers in China 2004 today,
a directory of over 130 Chinese manufacturers, an overview and analysis
of the emerging life science laboratory equipment industry in China,
20 profiles of leading companies, and case studies of two typical industry
leaders. The publication is essential for multinational life science
equipment manufacturers interested in sourcing, OEM or following China's
growing industry.
November 10, 2004
GB publishes Reagent & Consumable Manufacturers, China
2004
GB published Reagent and Consumable Manufacturers today, which includes
an overview and analysis of the emerging life science reagent and consumable
industry in china, a complete directory of over 55 reagent and 30 consumable
manufacturers, and 10 profiles of leading companies in the industry.
The publication provides a comprehensive resource for multinational
life science reagent and consumable manufacturers interested in sourcing,
OEM, or following the industry.
October 22, 2004
GB presents at Environmental Biotechnology meeting
GB presented at China's Environmental Microbiology Symposium 2004 to
a crowd of scientists and aspiring entrepreneurs. The talk, addressing
the market for remediation and other environmental biotechnologies,
was followed by talks on entrepreneurship by leadership from Siji Biotechnology.
October 20, 2004
GB publishes Pipeline China 2004, the first collection of innovative
drug candidates developed in China
GB published Pipeline China 2004 today, highlighting over 130 new drugs
under development in China. The report is a result of extensive research
by GB staff members and addresses biologics and small molecules in preclinical
and clinical development in China. The publication is essential for
business development professionals at pharmaceutical and biotechnology
companies interested in potential partnership with Chinese innovators.
September 15, 2004
GB publishes China Biotech 2004, an essential starting point
for anyone interested in China\'s emerging biotechnology industry
GB published China Biotech 2004, a directory of the over 250 biotechnology
companies and a 30 page overview of biotechnology development in China.
The publication focuses on what has been accomplished and what remains
to be done in China's fast-growing biotechnology industry.
July 30, 2004
General Biologic updates website, publications available for
online purchase
General Biologic completed an update of its website today, adding functionality
and information relevant to its client base. New sections include content
that explains our services for investors, biotechnology and pharmaceutical
companies, and suppliers to the biotechnology industry. Concurrently
with the website, GB has initiated an email-based newsletter that will
address the Chinese biotechnology industry growth and development.
June 6, 2004
General Biologic becomes one of the few Chinese members of
the Biotechnology Industry Association (BIO)
General Biologic has become one of the only companies with primary operations
in China to join BIO. We look forward to working together with other
members of the organization to address common issues that relate to
the biotechnology industry as a whole, and China in particular.
|
